Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Jun 23, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to identify patients with blunt trauma who are at low risk for serious abdominal or pelvic injuries. The goal is to develop a set of simple guidelines that doctors can use to decide when a CT scan is really necessary. Currently, many patients receive CT scans after trauma, which can expose them to unnecessary radiation and high medical costs, even when they may not have any injuries. By finding reliable criteria to identify those who are truly at risk, the trial aims to reduce the number of CT scans performed, thereby lowering costs and minimizing radiation exposure.
Patients eligible for this trial are those who have experienced blunt trauma and are undergoing a CT scan of their abdomen or pelvis in the emergency department. There are no specific exclusions, so anyone in this situation can potentially participate. During the trial, participants will undergo standard clinical evaluations to assess their injuries before any imaging is done. The researchers will then analyze the findings to develop and test the criteria that would help safely reduce the number of unnecessary scans. If successful, this could lead to safer, more efficient care for future trauma patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Blunt trauma patients who undergo abdominal-pelvic CT imaging during their initial trauma evaluation in the emergency department.
- Exclusion Criteria:
- • None
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
William R Mower, MD, PhD
Study Director
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials